Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Allogene Therapeutics (ALLO)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $12
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
JPMorgan Adjusts Allogene Therapeutics Price Target to $9 From $11, Maintains Overweight Rating
HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Allogene Therapeutics (ALLO), Zur Rose Group AG (Six Swiss: CH:DOCM) and Fresenius SE & Co. KGaA (GB:0OO9)
Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $18
Allogene Therapeutics Analyst Ratings
No Data